Cann Group has marked its first medicinal cannabis export to the UK, secured key German licenses, and reported a 42% revenue increase in Q3 2026 amid improving cash flow and strategic partnership talks.
- First medicinal cannabis export to UK completed
- German AMRadV licenses secured for European expansion
- 42% revenue growth over prior quarter
- 82% year-to-date improvement in cash outflows
- Strategic partnership and M&A discussions underway
First UK Medicinal Cannabis Export Signals Global Ambitions
Cann Group Limited (ASX:CAN) has officially opened its international export chapter with a shipment of approximately 120 kilograms of medicinal cannabis flower from its Mildura facility to the United Kingdom. This landmark delivery not only represents Cann’s first own-grown flower entering the UK market but also underscores its operational capability to meet stringent GMP and international regulatory standards, a critical hurdle in the tightly regulated medicinal cannabis industry.
Building on this momentum, Cann has secured AMRadV licences from Germany’s Federal Institute for Drugs and Medical Devices (BfarM), authorising the treatment of two medicinal cannabis products with ionising radiation. These licenses are pivotal for exporting to Germany, one of Europe’s largest medicinal cannabis markets, positioning Cann to accelerate its European distribution likely in the second half of 2026. This regulatory progress highlights the transferability of Cann’s Australian manufacturing quality systems to demanding overseas markets.
Revenue Growth and Operational Efficiency Drive Momentum
The company reported a 42% increase in revenue to $2.32 million for the quarter ended 31 March 2026 compared to the prior quarter, contributing to a year-to-date total of $6.84 million. This surge was fuelled by Cann’s strongest B2B purchase orders this financial year, reflecting growing demand amid supply chain uncertainties and stricter import controls that have made local supply more attractive. Notably, the commercialisation of trim material added a new revenue stream, accounting for 6% of quarterly orders, and the onboarding of a new white label customer alongside ongoing GMP contract packing discussions signal further growth potential.
Operationally, Cann has improved cash outflows from operations by 82% year-to-date to $1.3 million, edging closer to cash flow break-even. Payments to suppliers and staff fell 25% compared to the previous corresponding period and 8% versus the prior quarter, reflecting disciplined expense management. However, with only $330,000 in cash reserves and an estimated 0.25 quarters of funding available, liquidity remains tight. The company is actively negotiating with its debt provider for funding relief and exploring additional capital options, including a new loan secured by R&D tax refunds and potential equity raises, continuing the financial strategy evident in its recent $750k convertible note and prior debt restructures.
US Reclassification Could Boost Australian Producers
In a sector-wide positive development, the US Trump administration has reclassified FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III, reducing regulatory barriers and aligning federal policy more closely with state laws. This shift is expected to enhance clinical research and medical legitimacy for cannabis products, potentially attracting more institutional investment. For Cann, already operating under pharmaceutical-grade standards, this could open future opportunities for supply or collaboration with the US market, although the timeline and impact remain uncertain.
Domestic Market Challenges and Strategic Outlook
Domestically, Cann’s Botanitech brand is navigating a competitive and cautious prescribing environment marked by pricing pressure and regulatory uncertainty, especially for higher THC products. The company has responded by introducing lower THC options and expanding digital marketing efforts targeting healthcare professionals to maintain engagement and adapt to prescribing trends.
Looking ahead, Cann projects FY2026 revenue between $9.2 million and $10 million, with an EBITDA loss narrowing to $3.5–4 million, representing a 40% to 50% improvement over FY2025. Strategic partnership and M&A discussions are active, spanning acquisitions, partnerships, distribution, and product development, with an update expected before 30 June 2026. These moves could be pivotal in unlocking growth and enhancing shareholder value but come with inherent uncertainties around timing and outcomes.
Bottom Line?
Cann’s first UK export and German licensing mark a strategic leap, but tight cash reserves and reliance on funding negotiations underscore ongoing liquidity risk.
Questions in the middle?
- Will Cann’s strategic partnership talks translate into concrete growth or capital infusion before June?
- How will the US medical marijuana reclassification influence Cann’s export and collaboration prospects long term?
- Can Cann sustain its operational momentum and manage liquidity with only a quarter’s funding available?